The Eurasian Pharmaceutical Register was launched on March 1, 2021.
Its aims to inform interested parties about the exclusive rights to active pharmaceutical ingredients (API), processes of their production and medical use, protected in the Eurasian space.
The Eurasian Pharmaceutical Register includes information on Eurasian patents valid in the territory of 8 member states of the Eurasian Patent Organization, and on national patents from the EAPC Contracting states, as well as on registered medicinal products and license and other agreements. This is one of the significant advantages of the Eurasian Pharmaceutical Register.
The Eurasian Pharmaceutical Register provides the most comprehensive information on the existence of patent rights in relation to API. Thus, it presents an additional tool for patent owners to enforce their patent rights. It is a source of reliable and up-to-date information for a wide range of interested parties, ranging from API developers to those engaged in the registration of medicinal products and their introduction into the market.
The Pharmaceutical Register is a publicly available information resource that provides free access to the data contained therein, namely information on patents protecting both chemical compounds and biotechnological products. Moreover, it includes information on the processes of production of such products (since the process provides indirect protection to the obtained product), new combinations and medical uses of API.
Currently, the Eurasian Patent Office enters information in the Pharmaceutical Register both at the request of the patent owner and on its own initiative regarding Eurasian patents for which medicinal products are registered in the territories of the EAPC Contracting states. This is intended to maintain comprehensive information on patent rights, reflecting the informational nature of the register.
It functions under the Regulations on Eurasian Pharmaceutical Register (Regulations), approved at the forty-third (thirtieth regular) meeting of the Administrative Council of the Eurasian Patent Organization on December 5-7, 2023, and entered into force on December 7, 2023.
This document allows anyone to obtain extracts from the Pharmaceutical Register upon payment of the fee established by the EAPO. It also allows for amendments and additions to the Pharmaceutical Register, including the deletion of information from it.
The Regulations offer the option to recognize the information contained therein as official in order to attest to the patent protection of APIs, processes of their production and their medical use on the territory of the EAPC Contracting State. The Regulations provide for the possibility of concluding an agreement between a Contracting State and/or an international intergovernmental organization of which the Contracting State is a member, with the Eurasian Patent Organization, in order to recognize the information posted therein as official on the territory of a Contracting State. Data included in the Eurasian Pharmaceutical Register and recognized as official in a Contracting State may be used on its territory to ensure the enforcement of exclusive rights to protected API-related inventions, as well as their protection, including through the application of provisional measures established by the national legislation of the Contracting State.
The EAPO provides extracts from the Pharmaceutical Register at the request of patent owners for submission to competent authorities. These extracts can also be provided at the request of judicial and other competent authorities of the states.
The extract contains information on the compliance of the patented subject matter with a specific INN or combination of INN, indicating the claims of the Eurasian or, respectively, national patent protecting the API.